Iktomi, fwiw, GSK mentioned favorably in this week's Barron's.
Jeff Everett, chief investment officer of the Templeton Global Equity Group, a Franklin Resources unit said, "...the company trades at about 15 times estimated 2006 earnings, which is a low valuation for the business historically. And the shares really haven't gone anywhere, so in a positive business cycle that means there is a chance for more upside. And the company has been buying back shares, has virtually no debt and a cost of capital of about 5%. So with a return on equity in excess of 15%, that for us is a winning combination."
He also mentioned Sanofi favorably.
I'm holding very small amounts in both GSK and SNY. Although I'm looking for an opportunity to sell some of the pharma and healthcare stocks I'm holding, with these two - GSK and SNY - I'm looking to buy more. (JMO; I could be wrong. I've no skill in evaluating drug pipelines, competing products, patent expirations, etc.) |
